Apimeds Pharmaceuticals US (APUS) Cash from Financing Activities (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) reported Cash from Financing Activities of $8.5 million for Q4 2025, up 11001.54% on a YoY basis from N/an in Q4 2024, and down 28.39% quarter-over-quarter from $11.9 million in Q2 2025.
Apimeds Pharmaceuticals US (APUS) Cash from Financing Activities (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US has reported Cash from Financing Activities for 2 years, with the latest figure at $8.5 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 11001.54% year-over-year to $8.5 million; the trailing twelve-month figure through Dec 2025 stood at $20.6 million (changed N/A YoY), and the FY2025 full-year result was $20.6 million, up 6215.26% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $8.5 million, down from $11.9 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $11.9 million in Q2 2025, with the low at $76500.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Apimeds Pharmaceuticals US | 13.93 Mn | 10.29 Mn | - | 8.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.49 Mn |
| Dec 31, 2025 | 8.49 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Mar 31, 2025 | 267,200.00 |
| Mar 31, 2025 | 267,200.00 |
| Dec 31, 2024 | 76,500.00 |
| Dec 31, 2024 | 76,500.00 |
| Sep 30, 2024 | 150,000.00 |
| Sep 30, 2024 | 150,000.00 |